Media.Player

Microfluidic Device for Forming Monodisperse Lipoplexes

Technology Application

Gene therapy, gene transfection, drug delivery, plasmid DNA and shRNA for pharmaceutical and therapeutic applications

Detailed Technology Description

A microfluidic device using a picoliter micro-reactor and incubator (PMRI) system has been developed to improve the generation of cationic lipids and DNA. This system decreases the range of size distributions and improves the gene transformation rate. The device may be used for in vitro and in vivo gene therapy and these lipid-gene complexes may be used in gene therapy applications.

Supplementary Information

Patent Number: US7811603B2
Application Number: US2007746024A
Inventor: Lee, Abraham Phillip | Hsieh, Albert Tsung-Hsi
Priority Date: 9 May 2006
Priority Number: US7811603B2
Application Date: 8 May 2007
Publication Date: 12 Oct 2010
IPC Current: A61K0009127
US Class: 424450 | 2640041
Assignee Applicant: The Regents of the University of California
Title: Microfluidic device for forming monodisperse lipoplexes
Usefulness: Microfluidic device for forming monodisperse lipoplexes
Summary: For preparing monodisperse lipoplexes (claimed) which is useful for improving gene transfection and/or genetherapy.
Novelty: Preparing monodisperse lipoplexes, for improving gene therapy, has microfluidic device, first, second reactant fluid, hydrophobic fluid, and flowing first, second, hydrophobic fluid to droplet generation zone to generate lipoplexes

Industry

Biomedical

Sub Category

DNA/Gene Engineering

Application No.

7811603

Others

Tech ID/UC Case

18776/2006-644-0

Related Cases

2006-644-0

*Abstract

The determinant factor for the successful applications of delivering drugs is to develop a non-viral and efficient carrier. Cationic lipid based liposomal carriers are the most attractive non-viral solution. Advantages of liposomal vectors include safety, lack of immunogenicity, ability to package large DNA molecules and ease of preparation. However, the conventional processes for catatonic lipids and DNA complex formulation are normally irreproducible.

*IP Issue Date

Oct 12, 2010

*Principal Investigator

Name: Tsung-Hsi Hsieh

Department:

Name: Abraham Lee

Department:

Country/Region

USA